The global advanced therapies in biopharmaceutical medicine market is poised for substantial growth between 2025 and 2034, driven by rapid technological advancements, increasing demand for personalized treatments, and evolving healthcare priorities. These factors are reshaping the future of medicine and unlocking significant revenue potential across the sector.
The global advanced therapies in biopharmaceutical medicine market is driven by the accelerating prevalence of rare and life-threatening diseases, including genetic disorders and cancers, increasing R&D investments, and technological advancements. Major breakthroughs in gene editing technologies like CRISPR, along with advancements in cell and tissue engineering, are fueling the development of novel therapies, such as cell and gene therapies, and tissue-engineered products.
Get a look into key market insights, trends and forecasts with our free sample report: https://www.towardshealthcare.com/download-sample/5732
Advanced Therapies in Biopharmaceutical Medicine Market Highlights:
• North America led the market in 2024.
• Asia-Pacific is expected to grow at the fastest CAGR during 2025-2034.
• By therapy type, the gene therapy segment held a major revenue share of the market in 2024.
• By therapy type, the CAR-T segment is expected to grow at the fastest CAGR during the forecast period.
• By application type, the oncology segment was dominant in the advanced therapies in biopharmaceutical medicine market in 2024.
• By application type, the cardiovascular diseases segment is expected to register a rapid expansion in the upcoming years.
• By product type, the tissue-engineered products segment led the market in 2024.
• By product type, the combined ATMPs segment is expected to grow rapidly in the projected period.
• By distribution channel type, the hospital pharmacies segment registered dominance in the market in 2024.
• By distribution channel type, the online pharmacies segment is expected to grow at the fastest CAGR during 2025-2034.
• By end user, the hospital segment led the global advanced therapies in biopharmaceutical medicine market in 2024.
• By end user, the clinics segment is expected to show the fastest growth during the forecast period.
Market Overview
The advanced therapies in biopharmaceutical medicine market, primarily including gene, cell, and tissue-based therapies, represent a paradigm shift in treating issues by directly altering or substituting damaged genes, harnessing living cells, or regenerating damaged tissues. Nowadays, ongoing developments are raising clinical trial activity, advancements in manufacturing and regulatory frameworks, and widespread applications beyond rare diseases. These advances are focused on the regeneration or repair of damaged tissues and organs using cells, biomaterials, and bioactive molecules. Inclusion of regenerating cartilage and bone, especially in joint injury applications.
Access a comprehensive databook packed with segment-wise statistics, regional breakdowns, and market sizing: https://www.towardshealthcare.com/download-databook/5732
Broder Adoption in the Development of Various Therapies: Major Potential
Numerous applications are growing in the advanced therapies in biopharmaceutical medicine market, including the development of different therapies such as gene therapy, cell therapy, and tissue engineering. Gene therapies are widely adopted in growing inherited disorders, some cancers, and rare genetic conditions, such as cystic fibrosis. Besides this, cell therapies are employed in Parkinson's disease and a few kinds of cancers. On the other hand, a robust application of tissue engineering is used in burn victims and developing artificial cartilage for joint problems.
Emerging Production Constraints and High Expense: Major Challenges
Mainly, patient-specific production approaches are time-consuming and resource-intensive, and need strong and measurable supply chains are restrict the growth of the advanced therapies in the biopharmaceutical medicine market. As well as the emergence of high spending in the development of advanced therapies is challenging the market expansion.
The Advanced Therapies in Biopharmaceutical Medicine Market: Regional Analysis
North America held a major revenue share of the market in 2024. Mainly, this region’s market is fueled by the accelerating demand for tailored medicine by applying individual patient data, along with advancements in technologies, such as gene editing technologies, including CRISPR, and the progression of cell and gene therapies. However, this region is heavily involved in strategic partnerships with many companies to expand expertise, accelerate development, and mitigate financial risks.
Whereas, the US is greatly facing major expansion due to the rising outsourcing trend of manufacturing advanced therapy medicinal products (ATMPs) to Contract Development and Manufacturing Organizations (CDMOs), and an increase in clinical trials for advanced therapies with a novel and robust pipeline of treatments.
For instance,
• In May 2025, Azenta Life Sciences and Form Bio made a strategic partnership to advance AAV gene therapy development.
Canada is heavily involved in major investments in research and development (R&D) of advanced therapies, especially in cell and gene therapy, along with adaptable regulatory frameworks and rules from agencies that simplify the approval process, supporting innovation and commercialization.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
The Asia Pacific is expected to Grow Rapidly During the Forecast Period
Asia Pacific is anticipated to register rapid expansion in the upcoming years. By the contribution of several factors, like rising cases of chronic diseases such as cancer and heart conditions, are acting as major drivers for the advanced therapies in the biopharmaceutical medicine market growth. ASAP is also accelerating a surge of biologics and biosimilars development is driving the biopharmaceutical companies. Governments of ASAP countries and private leaders are broadly investing in R&D of advanced therapies is also boosting the market growth.
Although the advanced therapies in biopharmaceutical medicine market in China have a huge pool of pharmaceutical and biotechnology companies, which are increasingly involved in the development of numerous biologics, vaccines, biosimilars, and other important therapies, besides this, China’s government is widely encouraging research and development activities in the advancement of novel drug molecules used in many serious health conditions.
Wide range progression in clinical trials, development of different therapies in India, is propelling the advanced therapies in the biopharmaceutical medicine market. As well as increasing awareness about chronic disease with the adoption of advanced remedies in India, along with boosting collaborations with global companies by India is accelerating the overall market growth.
The Advanced Therapies in Biopharmaceutical Medicine Market: Segmentation Analysis
By therapy type analysis
The gene therapy segment dominated the market in 2024. The segment is driven by major investments from venture capital, pharmaceutical companies, and government bodies are impelling R&D, clinical trials, and the commercialization of gene therapies. Also, the breakthroughs in gene delivery technologies, such as viral and non-viral vectors, and genome editing technologies like CRISPR, are boosting the overall segment growth.
The CAR-T segment is estimated to grow at the fastest CAGR during 2025-2034. Around the globe, the escalating burden of cancer, especially hematological malignancies, with the rising number of approved CAR-T products and their evolving applications in diverse cancer types, like diffuse large B-cell lymphoma and multiple myeloma, is fueling the adoption of CAR-T and its expansion.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Latest Developments in the CAR-T Segment
|
Company |
Recent Drifts |
|
PromiCell (March 2025) |
Launched an accredited investor-only campaign to advance next-gen CAR T & TCR T cancer treatments |
|
CARsgen Therapeutics (February 2025) |
Introduced Zhuhai SB Xinchuang to escalate allogeneic CAR-T Cell products development in Mainland China |
|
Leveragen (January 2025) |
Partnered with Moonlight Bio to advance T cell therapies using proprietary fully human single-domain antibody technology |
|
Vyriad, Inc. (November 2024) |
Collaborated with Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. |
By application type analysis The oncology segment dominated the advanced
therapies in biopharmaceutical medicine market in 2024. Consistent growth in
cancer cases, with significant investment in research and development of novel
oncology drugs by numerous biopharmaceutical industries, including targeted
therapies and immunotherapies to boost the immune system against
cancer. Whereas, the cardiovascular diseases
segment will expand rapidly, due to the greater global burden of cardiovascular
disease (CVD), like heart failure, heart attack, the restriction of traditional
therapies, and the potential of advanced therapies like gene therapy and
biologics to highlight unmet needs. Along with biologics, such as monoclonal
antibodies and recombinant
proteins, can be created to alter specific biological pathways involved
in CVD. By product type analysis The tissue-engineered products segment was
dominant in the advanced therapies in biopharmaceutical medicine market in
2024. The segment is influenced by the growing demand
for regenerative medicines, along with the increasing incidence of
chronic and degenerative disorders. Also, the breakthroughs in tissue
engineering technologies, like biomaterials, stem
cell sourcing, tissue construct vascularization, and 3D
bioprinting, are impelling the segment growth. However, the combined ATMPs segment will
grow rapidly, due to the boost in clinical pipelines and regulatory approvals,
technological advancements in areas like gene editing and cell
engineering, as well as cell-based therapies embedded in scaffolds, which
are transforming through clinical trials, driving the segment growth. Elevate your
healthcare strategy with Towards Healthcare. Enhance efficiency and drive
better outcomes schedule a call today: https://www.towardshealthcare.com/schedule-meeting By distribution channel type analysis The hospital pharmacies segment held the
biggest share of the advanced therapies in biopharmaceutical medicine market in
2024. Due to rising demand for advanced therapies like biologics,
immunotherapies, and targeted oncology drugs, which require specialized
handling and administration in hospital pharmacies, this enhances patient care.
Hospitals possess robust and advanced hospital pharmacies, with a major
distribution of compounded drugs is assisting the segment expansion. The online pharmacies segment is predicted
to expand at a rapid CAGR because of escalating consumer preference for online
purchases, advancements in technology, and the growth
of personalized medicine. This segment is characterized by the
convenience, availability, and affordable coupled with purchasing medications
online. By end-user analysis The hospital segment dominated the global
advanced therapies in biopharmaceutical medicine market in 2024. Segment is
propelled by the accelerating prevalence of chronic diseases, technological
advancements in cell and gene therapies, and supportive government initiatives
enhancing biomanufacturing and healthcare access. The clinics segment is anticipated to grow
fastest during the forecast period. Widely impacting factors on the segment’s
expansion are increasing demand for cell and gene therapies, coupled with
advancements in related technologies. This expansion is further impelled
by the growing number of clinical trials and regulatory approvals, especially
for treatments targeting oncology, rare genetic disorders, and other complex
diseases. Top Companies and Their Contributions to
the Advanced Therapies in Biopharmaceutical
Medicine Market Company Contributions & Offerings in Advanced Therapies Pfizer Inc. Partnered with BioNTech on mRNA technology for vaccines; advancing
gene therapies for rare diseases like hemophilia and DMD. Johnson & Johnson Through Janssen, developing cell and gene therapies in oncology
and rare diseases; invested in CAR-T and RNA technologies. AbbVie Inc. Focuses on gene therapy for neurological and retinal disorders;
acquired Allergan to expand biopharma capabilities. F. Hoffmann-La Roche Active in cell therapy through subsidiary Genentech; advancing
personalized medicine in oncology and ophthalmology. Merck & Co. Inc. Invests in viral vector technologies and immune cell engineering;
collaborates on gene editing and regenerative therapies. Eli Lilly and Co. Expanding into gene therapy for diabetes and neurodegenerative
diseases, acquired Prevail Therapeutics. AstraZeneca Plc Leveraging mRNA and gene editing for rare diseases and cancer;
strong pipeline in cell-based immunotherapies. Novartis AG A pioneer in CAR-T (Kymriah), advancing gene therapies for spinal
muscular atrophy (Zolgensma) and eye diseases. Amgen Inc. Focuses on genetic medicines and oncology-based biotherapeutics;
uses viral vectors and RNA tech platforms. Novo Nordisk AS Investing in gene therapies for metabolic disorders; acquired
Dicerna to expand RNAi capabilities for rare and chronic diseases.
Advanced Therapies in Biopharmaceutical
Medicine Market Companies • Pfizer Inc. • Johnson & Johnson • AbbVie Inc. • F. Hoffmann-La Roche Ltd. • Merck & Co. Inc. • Eli Lilly and Co. • AstraZeneca Plc • Novartis AG • Amgen Inc • Novo Nordisk AS • Sanofi • Bristol-Myers Squibb Co • Regeneron Pharmaceuticals Inc. • GlaxoSmithKline Plc • Gilead Sciences Inc. • CSL Ltd. • Takeda Pharmaceutical Co. Ltd. • Moderna Inc. • Vertex Pharmaceuticals Inc. • Bayer AG Browse More Insights of Towards
Healthcare: The global biopharmaceuticals
Contract Research Organization (CRO) market is on a strong upward
trajectory and is expected to generate substantial revenue growth, potentially
reaching hundreds of millions over the forecast period from 2025 to 2034. The global biopharmaceutical
third-party logistics market is valued at USD 143.44 billion in 2024,
expected to grow to USD 152.93 billion in 2025, and is projected to reach
approximately USD 276.24 billion by 2034. The U.S.
biopharmaceutical third-party logistics market is valued at USD 56.77
billion in 2024, growing to USD 61.08 billion in 2025, and is anticipated to
reach around USD 118.12 billion by 2034, expanding at a CAGR of 7.6% between
2025 and 2034. The global antibody
therapy market is estimated at USD 278.25 billion in 2024, projected to
increase to USD 314.64 billion in 2025, and expected to reach approximately USD
951.24 billion by 2034, growing at a CAGR of 13.08% from 2025 to 2034. The global next-generation
therapies market is experiencing rapid expansion and is poised for
substantial revenue growth, with projections indicating significant value
generation in the hundreds of millions during the 2025 to 2034 forecast period. The global AAV
(Adeno-Associated Virus) gene therapy market is undergoing significant
growth, with projections suggesting revenue will reach several hundred million
dollars by the end of the forecast period from 2025 to 2034. The global mechanobiology-centered
therapy market is emerging as a promising field and is expected to
witness substantial revenue growth throughout the forecast period from 2024 to
2034. The global viral
vector gene therapy market is gaining strong momentum, with
expectations of significant revenue expansion from 2025 through 2034. The global CAR-T
cell therapy isolator market is on a robust growth path, anticipated to
achieve substantial revenue gains, potentially reaching hundreds of millions
between 2025 and 2034. The exosome
cell and gene therapy market is emerging as a high-potential segment
due to its growing application in the treatment of chronic conditions, with oncology
being one of its major therapeutic areas. How is the Advanced Therapies in
Biopharmaceutical Medicine Market Progressing? • In July 2025, Vie Ventures, a new life
sciences venture capital firm, launched advanced next-generation therapies for
autoimmune diseases. • In May 2025, Stylus Medicine, a biotech
startup, was introduced with $85m to advance in vivo gene editing therapies. • In May 2025, BIH partnered with BioLabs
to launch a Clinical Incubator for Biomedical Translation of Advanced Therapy Medicinal
Products (ATMPs). • In April 2025, Thermo Fisher Scientific
inaugurated its Advanced Therapies Collaboration Center (ATxCC) in San Diego to
support the expansion of cell therapy development. • In January 2025, Lutris Pharma, a
clinical-stage biopharmaceutical company, secured a $30 million financing
to advance the development of LUT014, an innovative topically applied gel aimed
at eliminating EGFRi-induced rashes. Advanced Therapies in Biopharmaceutical
Medicine Market Segmentation By Therapy Type • Gene Therapy • Cell Therapy • Stem Cell Therapy • Non-Stem Cell Therapy • CAR-T Therapy • Tissue-Engineered Products • Others (e.g., combined ATMPs,
biodegradable scaffolds) By Application • Oncology • Cardiovascular Diseases • Musculoskeletal Disorders • Dermatology • Others (e.g., ophthalmology, neurology,
immunology) By Product Type • Tissue-Engineered Products • Somatic Cell Therapy Products • Combined ATMPs • Others By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others By End-User • Hospitals • Clinics • Others (e.g., research institutions,
home care) By Region • North America • U.S. • Canada • Asia Pacific • China • Japan • India • South Korea • Thailand • Europe • Germany • UK • France • Italy • Spain • Sweden • Denmark • Norway • Latin America • Brazil • Mexico • Argentina • Middle East and Africa (MEA) • South Africa • UAE • Saudi Arabia • Kuwait Access the complete market intelligence
report with in-depth analysis, strategic insights and future outlook: https://www.towardshealthcare.com/price/5732 You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com Gain access to the
latest insights and statistics in the healthcare industry by subscribing to our
Annual Membership. Stay updated on healthcare industry segmentation with
detailed reports, market trends, and expert analysis tailored to your needs.
Stay ahead of the curve with valuable resources and strategic recommendations.
Join today to unlock a wealth of knowledge and opportunities in the dynamic
world of healthcare: Get a Subscription About Us Towards
Healthcare is a leading global provider of
technological solutions, clinical research services, and advanced analytics,
with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we
build strategic partnerships that generate actionable insights and
transformative breakthroughs. As a global strategy consulting firm, we empower
life science leaders to gain a competitive edge, drive research excellence, and
accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards
Automotive | Towards Food and
Beverages | Towards
Chemical and Materials | Towards Consumer
Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
